Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zai Lab (ZLAB) Cash & Equivalents (2018 - 2025)

Zai Lab (ZLAB) has disclosed Cash & Equivalents for 8 consecutive years, with $679.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 58534.43% to $679.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $679.6 million through Dec 2025, up 58534.43% year-over-year, with the annual reading at $679.6 million for FY2025, 58534.43% up from the prior year.
  • Cash & Equivalents hit $679.6 million in Q4 2025 for Zai Lab, down from $717.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.8 billion in Q2 2021 to a low of $1.0 million in Q4 2022.
  • Historically, Cash & Equivalents has averaged $572.1 million across 5 years, with a median of $680.2 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: tumbled 99.9% in 2023 and later skyrocketed 67876.93% in 2025.
  • Year by year, Cash & Equivalents stood at $964.1 million in 2021, then crashed by 99.89% to $1.0 million in 2022, then rose by 5.06% to $1.1 million in 2023, then grew by 5.36% to $1.2 million in 2024, then surged by 58534.43% to $679.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for ZLAB at $679.6 million in Q4 2025, $717.2 million in Q3 2025, and $1.2 million in Q2 2025.